The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis

被引:1
|
作者
Lv, Qiong [1 ,2 ]
Zhao, Huashan [2 ,3 ,4 ,5 ]
机构
[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Electrocardiogram, Luoyang, Peoples R China
[2] Henan Univ Sci & Technol, Coll Clin Med, Luoyang, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gen Med, Luoyang, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gen Med, 24 Jinghua Rd, Luoyang, Henan, Peoples R China
[5] Henan Univ Sci & Technol, Coll Clin Med, 24 Jinghua Rd, Luoyang, Henan, Peoples R China
关键词
Association; MI; mASLD; risk factors; FATTY LIVER; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; MANAGEMENT; ELEVATION; MORTALITY;
D O I
10.1080/07853890.2024.2306192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective While studies have documented how metabolic dysfunction-associated steatotic liver disease (MASLD) can contribute to cardiovascular disease (CVD), whether MASLD is associated with myocardial infarction (MI) remains debateable. Herein, we systematically reviewed published articles and performed a meta-analysis to determine the relationship between MASLD and MI risk.Methods PubMed, MEDLINE, Embase, Web of Science, CNKI, CBM, VIP, and WanFang databases were searched, and the DerSimonian Laird method was used to obtain hazard ratios (HRs) for binary variables to assess the correlation between MASLD and MI risk. Subgroup analyses for the study region, MASLD diagnosis, quality score, study design, and follow-up time were conducted simultaneously for the selected studies retrieved from the time of database establishment to March 2022. All study procedures were independently conducted by two investigators.Results The final analysis included seven articles, including eight prospective and two retrospective cohort studies. The MI risk was higher among MASLD patients than among non-MASLD patients (HR = 1.26; 95% CI: 1.08-1.47, p = 0.003). The results of the subgroup analysis of the study region revealed an association of MASLD with MI risk among Americans and Asians, but not in Europeans. Subgroup analyses of MASLD diagnosis showed that ultrasonography and other (fatty liver index[FLI] and computed tomography [CT)]) diagnostic methods, but not international classification of disease (ICD), increased the risk of MI. Subgroup analysis of the study design demonstrated a stronger relationship between MASLD and MI in retrospective studies but not in prospective studies. Subgroup analysis based on the follow-up duration revealed the association of MASLD with MI risk in cases with < 3 years of follow-up but not with >= 3 years of follow-up.Conclusion MASLD increases the risk of MI, independent of traditional risk factors.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] New Therapeutic Approaches for the Treatment of Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Increased Cardiovascular Risk
    Brankovic, Marija
    Dukic, Marija
    Gmizic, Tijana
    Popadic, Viseslav
    Nikolic, Novica
    Sekulic, Ana
    Brajkovic, Milica
    Dokic, Jelena
    Mahmutovic, Edvin
    Lasica, Ratko
    Vojnovic, Marko
    Milovanovic, Tamara
    [J]. DIAGNOSTICS, 2024, 14 (02)
  • [42] Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis
    Malandris, Konstantinos
    Katsoula, Anastasia
    Liakos, Aris
    Bekiari, Eleni
    Karagiannis, Thomas
    Theocharidou, Eleni
    Giouleme, Olga
    Sinakos, Emmanouil
    Tsapas, Apostolos
    [J]. ANNALS OF GASTROENTEROLOGY, 2024, 37 (05):
  • [43] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    [J]. MATURITAS, 2024, 186
  • [44] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    [J]. CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [45] Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents
    Maldonado-Rojas, Andrea del Carmen
    Zuarth-Vazquez, Julia Maria
    Uribe, Misael
    Barbero-Becerra, Varenka J.
    [J]. ANNALS OF HEPATOLOGY, 2024, 29 (02)
  • [46] Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Singh, Avneet
    Buckholz, Adam
    Kumar, Sonal
    Newberry, Carolyn
    [J]. NUTRIENTS, 2024, 16 (05)
  • [47] Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
    Sandireddy, Reddemma
    Sakthivel, Suganya
    Gupta, Priyanka
    Behari, Jatin
    Tripathi, Madhulika
    Singh, Brijesh Kumar
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [48] The Role of Endoplasmic Reticulum in Lipotoxicity during Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Pathogenesis
    Venkatesan, Nanditha
    Doskey, Luke C.
    Malhi, Harmeet
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2023, 193 (12): : 1887 - 1899
  • [49] The Lasting Effects of COVID-19 on the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Backer, Sean
    Khanna, Deepesh
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [50] Associating Appendicitis with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Novel Insight into an Unexpected Connection
    Roderburg, Christoph
    Waldschmidt, Dirk
    Leyh, Catherine
    Krieg, Sarah
    Krieg, Andreas
    Luedde, Tom
    Loosen, Sven H.
    Kostev, Karel
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)